Zymeworks ZYME 深 滬
等待開盤 11-04 09:30:00 美东时间
30.13
+1.140
+3.93%
華盛通- 最 高30.40
- 今 開29.41
- 成交量 251.97万股
- 最 低 29.20
- 昨 收 28.99
- 總市值 21.23亿
- 52周最高 31.34
- 市盈率 靜 --
- 換手率 3.58%
- 52周最低 21.52
- 委 比 53.85%
- 總股本 7047.54万
- 歷史最高 59.03
- 量 比 1.85
- 振 幅 4.14%
- 歷史最低 4.11
- 每 手 1
- 風險率 2.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Zymeworks Inc.收跌0.35%，成交额6550.33万美元
10月31日，Zymeworks Inc.（ZYME）收跌0.35%，报28.61美元，成交额6550.33万美元，市值20.3亿美元。 行情数据 • 开盘价...
10-31 05:26
美股大行评级 | 潜在涨幅163.5%！BTIG上调Cullinan Therapeutics目标价至41美元，维持"买入"评级
今日重点评级关注：BTIG：维持Cullinan Therapeutics"买入"评级，目标价从40美元升至41美元；Rosenblatt：维持SK海力士"买入"评级，目标价从320美元升至400美元
10-29 12:30
Zymeworks Inc.收涨0.53%，成交额2336.96万美元
10月27日，Zymeworks Inc.（ZYME）收涨0.53%，报28.37美元，成交额2336.96万美元，市值20.13亿美元。 行情数据 • 开盘价...
10-27 05:27
Zymeworks Enters Global License And Collaboration Agreement With Roche For Research, Development And Commercialization Of ZW209; Company Eligible For Upfront Payment Of $55M, With $40M Payment Upon Initiation Of Phase 1b Trial, And Additional Milestone Payments Of Up To $718M
Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’s Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche U.S. FDA IND clearance received with additional global...
10-23 18:05
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
Zymeworks has entered into a global license and collaboration agreement with Roche for the development and commercialization of ZW209, a T cell engager targeting DLL3. Under the agreement, Zymeworks is eligible to receive a $55 million upfront payment, a $40 million payment upon initiation of the Phase 1b trial, and additional milestone payments of up to $718 million, along with tiered royalties on future net sales. Zymeworks will conduct the Pha...
10-23 10:00
Zymeworks Inc.收跌2.8%，成交额1599.78万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 05:31
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results
Zymeworks Inc. announced it will report its third quarter 2026 financial results on November 9, 2026, after market close. The company will not host a conference call or webcast for the results. Management will participate in several upcoming investor conferences in New York and London, including the Wolfe Research Healthcare Conference, Stifel Healthcare Conference, Truist Securities BioPharma Symposium, and Jefferies Global Healthcare Conference...
10-15 10:00
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $34
Truist Securities analyst Gregory Renza maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $32 to $34.
10-08 01:21
Nuvation, Jazz gain new Buys at Citi on oncology prospects
Citi launched its coverage of Nuvation Bio (NUVB) and Jazz Pharmaceuticals (JAZZ) with Buy ratings on Wednesday as part of a broader review of the U.S. biopharma sector, highlighting the companies' on...
10-01 01:47
